Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • HR+ • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic
What is your approach to chemoprevention for HR+ DCIS in the ipsilateral breast in a patient who already completed 7 years of an AI for a prior HR+ invasive breast cancer?
Patient underwent mastectomy for DCIS in the setting of previous lumpectomy and adjuvant radiation for the invasive breast cancer.
Answer from: Medical Oncologist at Academic Institution
This is a not-uncommon scenario. What is the appropriate use of endocrine therapy after ipsilateral breast tumor recurrence or second primary breast cancer in a patient who has recently completed hormonal therapy?As shown in the Breast Cancer Prevention Trial (P-1), MAP.3, and IBIS II, both SERMs an...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
In this case, chemo prevention is obviously for the contralateral breast. I agree with Dr. @Saundra S. Buys in considering an AI or tamoxifen if prior ET was more than 5 years ago. What is the use of switching to another AI or tamoxifen for chemo prevention while they are already on ET for inva...